Skip to main content
Erschienen in: Journal of Gastroenterology 5/2016

18.02.2016 | Letter to the Editor

Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

verfasst von: Takeshi Yamada, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Ichisnosuke Hyodo

Erschienen in: Journal of Gastroenterology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Excerpt

Since the ToGA study demonstrated that patients with HER2-positive gastric cancer benefit from trastuzumab in addition to 5-fluorouracil/capecitabine plus cisplatin, trastuzumab is used worldwide with standard chemotherapy. However, not all patients with HER2-overexpressing tumors respond to trastuzumab treatment, and further exploring useful biomarkers is needed. HER2 extracellular domain (ECD) shed into circulation from tumor cells has been reported as a good biomarker for probing HER2 overexpression and monitoring its dynamic change, which reflects a patient’s response to therapy in breast cancer [1]. Recently, Zhou et al. first reported the significant correlation between serum level of HER2 ECD and efficacies of trastuzumab-containing chemotherapy for advanced gastric cancer in the Journal of Gastroenterology [2]. This study is highly impactful to the readership but some points to be discussed seem lacking. …
Literatur
1.
Zurück zum Zitat Lam L, McAndrew N, Yee M, et al. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012;1826:199–208.PubMedPubMedCentral Lam L, McAndrew N, Yee M, et al. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012;1826:199–208.PubMedPubMedCentral
2.
Zurück zum Zitat Zhou J, Peng Z, Liu Y, et al. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. J Gastroenterol. 2015;50:955–61.CrossRefPubMed Zhou J, Peng Z, Liu Y, et al. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. J Gastroenterol. 2015;50:955–61.CrossRefPubMed
3.
Zurück zum Zitat Hyodo I. Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer? Gastric Cancer. 2012;15:115–7.CrossRefPubMed Hyodo I. Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer? Gastric Cancer. 2012;15:115–7.CrossRefPubMed
Metadaten
Titel
Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?
verfasst von
Takeshi Yamada
Yoshiyuki Yamamoto
Toshikazu Moriwaki
Ichisnosuke Hyodo
Publikationsdatum
18.02.2016
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 5/2016
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1184-2

Weitere Artikel der Ausgabe 5/2016

Journal of Gastroenterology 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.